One frequent mutation is the amplification of the receptor tyrosine kinase EGFR, which occurs in almost 60% of primary GBM [4] and is associated with a worse prognosis [5, 6] Increased EGFR activity leads to enhanced signaling in several tumor associated downstream pathways like RAS or PI3K (reviewed in [7] and [8]). This evidence concerns the gene EGFR and glioblastoma.